Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602)

Renal Cell Carcinoma Clinical Trial

— UNISoN  

Official title:

A Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602).

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03177239
• Other study ID #: ANZUP 1602
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: October 19, 2017
• Est. completion date: December 31, 2022

Study information

• Verified date: February 2022
• Source: Australian and New Zealand Urogenital and Prostate Cancer Trials Group
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aims to evaluate the safety, tolerability and effectiveness of new treatments for kidney cancer called Nivolumab and Ipilimumab. The study is in two parts; in the first instance patients receive nivolumab alone. If this treatment is not effective patients may move onto the second part of the trial, where they receive nivolumab + ipilimumab. There is no placebo. The reason to offer one treatment alone, followed by two treatments together is that it is thought that the double treatment may have more side-effects, but also may be effective in people in whom the single first treatment (nivolumab alone) has not helped. Nivolumab and ipilimumab are experimental treatments. This means that they are not an approved treatment for non-clear cell kidney cancer in Australia. The purpose of this study is to test the effectiveness, safety, and tolerability of Nivolumab (also known as Opdivo or BMS-936558) and Ipilumumab (also known as MDX-010 or Yervoy). Nivolumab and ipilimumab are antibodies (a type of human protein) that are being tested to see if they will allow the body's immune system to work against tumour cells. The immune system is the body's defence against cancer, bacteria and viruses. The effectiveness of nivolumab and ipilimumab in cancer of the kidney will be assessed by measuring the size of patient tumours via CT scans. Nivolumab and ipilimumab have been used alone or in combination in many other cancers, and are licenced for use in other cancers like advanced melanoma and bladder cancer in Australia. They have not been tested in people with non-clear cell kidney cancer. About 85 participants with non-clear cell kidney cancer are expected to participate in this study, from Australia and New Zealand. This research study has been initiated by Dr. Craig Gedye, is being conducted in collaboration with the Centre for Biostatistics and Clinical Trials (BaCT) and sponsored in Australia by the Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group Pty Ltd. Bristol Myers Squibb (BMS) is supplying the study drugs and grant funding for this research.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 85
• Est. completion date: December 31, 2022
• Est. primary completion date: December 31, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Histologically confirmed unresectable, locally advanced (defined as disease not amenable to curative surgery or radiation therapy) or metastatic nccRCC (both treatment-naïve or those treated with a VEGFR TKI or another systemic medical

therapy). Non-clear cell histology including:

• Papillary renal cell carcinoma (type 1)
• Papillary renal cell carcinoma (type 2)
• Other: including chromophobe renal cell carcinoma, pure sarcomatoid renal cell carcinoma, Xp11 translocation (TFE3+ IHC) carcinoma, other renal carcinoma NOS

2. Be =18 years of age on the day of signing informed consent

3. At least 1 target lesion according to RECIST v1.1.

4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

5. Adequate bone marrow function (should be performed within 14 days prior to

registration and with values within the ranges specified below):

• Haemoglobin = 90g/L
• Platelets = 100x109/L
• Neutrophil count = 1.5x109/L

6. Adequate liver function (should be performed within 14 days prior to registration and

with values within the ranges specified below):

• Bilirubin = 1.5 x upper limit of normal (ULN) except for participants with known Gilbert's syndrome who can have total bilirubin < 3.0 mg/dL
• AST or ALT = 3.0 x ULN (or = 5.0x ULN in the presence of liver metastases)

7. Adequate renal function (should be performed within 14 days prior to registration and

with values within the ranges specified below):

• Creatinine = 1.5x ULN OR
• Creatinine clearance (CrCl) = 30mL/min (use Cockcroft-Gault Formula)

8. Female participants of childbearing potential should have a negative urine or serum pregnancy within 24 hours prior to registering the patient. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.

9. Female participants of childbearing potential should be willing to use two methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through to 5 months after the last dose of study medication. Participants of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year.

10. Male participants should agree to use an adequate method of contraception starting with the first dose of study therapy through to 7 months after the last dose of study therapy.

11. Able to provide a formalin-fixed paraffin embedded (FFPE) tumour block, representative of the participant's primary or metastatic disease (preferred), which must be forwarded to the Centre for Biostatistics and Clinical Trials (BaCT) within 10 working days post registration

12. Willing and able to start treatment within 14 days of registration, and to comply with all study requirements, including the timing and/or nature of the required treatment and assessments

13. Has provided signed, written informed consent.

Exclusion Criteria:

1. Urothelial or transitional cell carcinoma of the renal pelvis or ureter

2. Predominant clear cell renal cell carcinoma. A minority of clear cell histology (<50%) is acceptable, but there must be >50% non-clear cell histology predominant.

3. Participation in a study of an investigational agent within 30 days of registration.

4. Prior treatment with nivolumab, ipilimumab, or with any other anti-PD-1, anti-PD-L1, Anti-PD-L2, anti-CTLA-4 antibody or any other antibody or drug specifically targeting T cell co-stimulation or immune checkpoint pathways (NB Participant is eligible for Part 2 of the study if they took nivolumab monotherapy in Part 1 of the study).

5. Active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.

6. Any condition requiring systemic treatment with either corticosteroids (>10mg daily prednisone or equivalent dose of alternative corticosteroid) or other immunosuppressive medications within 14 days of registration. Intranasal, inhaled or topical steroids are permitted in the absence of active autoimmune disease. Participants are permitted to enrol if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger.

7. Untreated brain or leptomeningeal metastases or current clinical or radiological progression of known brain metastases or requirement for steroid therapy for brain metastases. Participants with treated brain metastases are eligible if they have been stable and off steroids for = 3 weeks.

8. Prior allogeneic organ transplant, inflammatory bowel disease, pneumonitis, tuberculosis, or primary immunodeficiency

9. Active infection requiring systemic therapy within 14 days before registration.

10. Receipt of live attenuated vaccination within 30 days of registration.

11. Life expectancy of less than 3 months.

12. Prior systemic therapy, surgery or radiation therapy within 4 weeks before registration. Note: If the participant has undergone major surgery, they must have recovered adequately before registration. Prior treatments with radiation therapy in the adjuvant and/or metastatic setting is permitted provided that therapy and is completed at least 14 days prior to the first dose of study drug and all treatment related adverse events are < Grade 1 at the time of registration.

13. History of another active malignancy within the previous 5 years, except for locally curable cancers that have been apparently cured, such as low-grade thyroid carcinoma, prostate cancer not requiring treatment (Gleason grade = 6), basal or squamous cell skin cancer, superficial bladder cancer, melanoma in situ or carcinoma in situ of the prostate, cervix, or breast. Participants who have been free of other malignancies for = 5 years prior to registration are eligible for this study.

14. Positive test for hepatitis B virus surface antigen (HBVsAg) or antibodies to hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection.

15. A history of other significant infection, including HIV. HIV testing is not mandatory unless clinically indicated.

16. Participants should be excluded if they have a history of allergy to study drug components, or a history of severe hypersensitivity reaction to any monoclonal antibody.

17. Serious medical or psychiatric conditions that might limit the ability of the patient to comply with the protocol

18. Female patient is pregnant or lactating.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Renal Cell
• Chromophobe Renal Cell Carcinoma
• Papillary Renal Cell Carcinoma Type 1
• Papillary Renal Cell Carcinoma Type 2
• Renal Cell Carcinoma
• Sarcomatoid Renal Cell Carcinoma
• Xp11 Translocation Carcinoma

Intervention

Drug:
• Nivolumab
Dosage Form: Nivolumab BMS-936558-01 Solution for Injection Potency: 100 mg (10 mg/mL) Primary Packaging: 10 mL vial Appearance: Clear to opalescent colourless to pale yellow liquid. May contain particles. Storage Condition: 2 to 8°C. Protect from light and freezing.
• Ipilimumab
Dosage Form: Ipilimumab Solution for Injection Potency: 200 mg (5 mg/mL) Primary Packaging: 40 mL vial Appearance: Clear, colourless to pale yellow liquid. May contain particles. Storage Condition: 2 to 8°C. Protect from light and freezing.

Locations

Country	Name	City	State
Australia	Ashford Cancer Centre	Adelaide	South Australia
Australia	Flinders Medical Centre	Adelaide	South Australia
Australia	Border Medical Oncology	Albury	New South Wales
Australia	Ballarat Oncology & Haematology Services	Ballarat	Victoria
Australia	Sunshine Coast University Hospital	Birtinya	Queensland
Australia	Box Hill Hospital - Eastern Health	Box Hill	Victoria
Australia	Royal Brisbane & Women's Hospital	Brisbane	Queensland
Australia	Campbelltown Hospital	Campbelltown	New South Wales
Australia	Chris O'Brien Lifehouse	Camperdown	New South Wales
Australia	Monash Medical Centre	Clayton	Victoria
Australia	St Vincents Hospital	Darlinghurst	New South Wales
Australia	Northern Cancer Institute	Frenchs Forest	New South Wales
Australia	St. George Hospital	Kogarah	New South Wales
Australia	Fiona Stanley Hospital	Murdoch	Western Australia
Australia	Calvary Mater Newcastle	Newcastle	New South Wales
Australia	Port Macquarie Base Hospital	Port Macquarie	New South Wales
Australia	Prince of Wales Hospital	Randwick	New South Wales
Australia	Tamworth Hospital - North West Cancer Centre	Tamworth	New South Wales
Australia	Westmead Hospital	Westmead	New South Wales

Sponsors (2)

Lead Sponsor	Collaborator
Australian and New Zealand Urogenital and Prostate Cancer Trials Group	Bristol-Myers Squibb

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	The biomarkers of response and resistance to anti-cancer treatments, as assessed by gene expression arrays, cytokine arrays, multiplex immunohistochemistry and mass cytometry on tissue and blood samples.		Through study completion, on average 5 years.
Primary	The objective tumour response rate, as assessed by RECIST1.1	This is defined as the proportion of participants in the analysis set with a confirmed complete response (CR) or partial response (PR) divided by the number of participants in the analysis set.	Through study completion, on average 5 years.
Secondary	Duration of objective tumour response, as assessed by RECIST1.1	Measured from the time measurement criteria are first met for CR/PR (whichever is first recorded) until the first date that progressive disease is objectively documented.	Through study completion, on average 5 years.
Secondary	Progression-free survival (PFS), as assessed by RECIST1.1	For Part 1, PFS is defined as the interval from date of registration to the date of first evidence of disease progression or death, whichever occurs first. For Part 2, PFS is defined as the interval from date of progressive disease on nivolumab monotherapy until the date of first evidence of disease progression or death, whichever occurs first.	Through study completion, on average 5 years.
Secondary	Immune-related tumour response rate, as assessed by irRECIST.	Defined as the proportion of participants in the analysis set with an immune related complete response (irCR), or immune related partial response (irPR), divided by the number of participants in the analysis set.	Through study completion, on average 5 years.
Secondary	Immune-related disease control rate (irDCR6), as assessed by irRECIST.	For Part 1, irDCR6 is defined as an assessment of CR or iPR or iSD according to modified irRECIST. For Part 2, irDCR6 is defined in the same way except that the extent of disease defining the baseline tumour burden is measured at the date of disease progression on nivolumab monotherapy.	At 6 months during treatment.
Secondary	The number of patients alive at the end of the study, as assessed by date of death.	Overall survival (OS) is defined as the time between the date of registration to part 1 of the study and the date of death due to any cause.	Through study completion, on average 5 years.
Secondary	The number of patients with adverse events, particularly immune-related adverse events, that are related to study drug, as assessed and graded according to CTCAE v4.03.		From time of patient registration, until 30 days after the last dose of treatment.
Secondary	The number of participants with permanent discontinuation of treatment or delays due to toxicity, as assessed and graded according to CTCAE v4.03.		From time of patient registration, until 30 days after the last dose of treatment.

External Links

•   Sponsor's website